Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

04.03.2024

1 Am J Clin Oncol
1 Am J Epidemiol
2 Am J Surg
1 Ann Oncol
2 Ann Surg Oncol
4 Anticancer Res
7 Breast Cancer
1 Breast Cancer (Auckl)
4 Breast Cancer Res
4 Breast Cancer Res Treat
1 Breast J
3 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
3 Cancer Lett
5 Clin Breast Cancer
2 Eur J Surg Oncol
1 Eur Radiol
1 Exp Cell Res
1 Int J Oncol
3 Int J Radiat Oncol Biol Phys
5 J Clin Oncol
1 J Natl Cancer Inst
1 Lancet Oncol
2 Mod Pathol
2 NPJ Breast Cancer
4 Oncogene
1 Oncology
7 PLoS One



    Am J Clin Oncol

  1. MISTRY T, Nath A, Pal R, Ghosh S, et al
    Emerging Futuristic Targeted Therapeutics: A Comprising Study Towards a New Era for the Management of TNBC.
    Am J Clin Oncol. 2024;47:132-148.
    >> Share


    Am J Epidemiol

  2. CHANG CJ, Ish JL, Chang VC, Daniel M, et al
    Exposure to Per- and Polyfluoroalkyl Substances and Breast Cancer Risk: A Systematic Review and Meta-analysis of Epidemiologic Studies.
    Am J Epidemiol. 2024 Feb 23:kwae010. doi: 10.1093.
    >> Share


    Am J Surg

  3. CORTINA CS, Kong AL
    Should surgeons reconsider the role of intraoperative sentinel lymph node evaluation for premenopausal breast cancer patients in the era of RxPONDER?
    Am J Surg. 2024 Feb 17:S0002-9610(24)00123-5. doi: 10.1016/j.amjsurg.2024.
    >> Share

  4. ESCANDON JM, Langstein HN, Christiano JG, Aristizabal A, et al
    Latissimus dorsi flap with immediate fat transfer (LIFT) for autologous breast reconstruction: Single institution experience.
    Am J Surg. 2024;228:185-191.
    >> Share


    Ann Oncol

  5. GENNARI A, Brain E, De Censi A, Nanni O, et al
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET.
    Ann Oncol. 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.
    >> Share


    Ann Surg Oncol

  6. JAKUB JW, Advani P, Maxwell R, Vallow L, et al
    SOUND (Sentinel Node Versus Observation After Axillary Ultrasound) Trial: Are We Ready to Change the Tune of Our Breast Cancer Practice?
    Ann Surg Oncol. 2024 Feb 28. doi: 10.1245/s10434-024-15111.
    >> Share

  7. COSTARELLI L, Arienzo F, Broglia L, La Pinta M, et al
    Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?
    Ann Surg Oncol. 2024 Mar 1. doi: 10.1245/s10434-024-15052.
    >> Share


    Anticancer Res

  8. SHIN JK, Kim HS, Yoon S
    Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
    Anticancer Res. 2024;44:1051-1062.
    >> Share

  9. JANG SY, Kim J, Hong E, Yang YJ, et al
    Phloretin Inhibits the Proliferation of Breast Cancer Cells Through the Down-regulation of Estrogen Receptor alpha.
    Anticancer Res. 2024;44:1109-1120.
    >> Share

  10. COLLERY P, Prunier C, Dosda E, Viallet J, et al
    Effectiveness of Rhenium(I)-diselenoether Low Doses in a Triple-negative Breast Cancer Chicken Embryo Model.
    Anticancer Res. 2024;44:941-951.
    >> Share

  11. YANG DK, Tungalag T, Lee SJ, Kim SJ, et al
    Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2024;44:1087-1095.
    >> Share


    Breast Cancer

  12. WONG HH, Cojocaru E, Watkins J, James S, et al
    Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
    Breast Cancer. 2024;31:272-282.
    >> Share

  13. WU X, Gui Y, Liu J, Li S, et al
    Patient-reported outcomes of mesh in minimally invasive (laparoscopic/robot-assisted) immediate subpectoral prosthesis breast reconstruction: a retrospective study.
    Breast Cancer. 2024;31:243-251.
    >> Share

  14. AOYAMA Y, Hoshino E, Shimomura A, Shimizu C, et al
    Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
    Breast Cancer. 2024;31:234-242.
    >> Share

  15. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
    Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Breast Cancer. 2024;31:217-227.
    >> Share

  16. PARIJA M, Prakash S, Krishna BM, Dash S, et al
    SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor beta.
    Breast Cancer. 2024 Feb 29. doi: 10.1007/s12282-024-01555.
    >> Share

  17. KASAHARA M, Kanematsu S, Tanaka Y, Okazaki S, et al
    Clinical benefits of tomosynthesis-guided vacuum assisted breast biopsy: a comparison with stereotactic vacuum assisted biopsy.
    Breast Cancer. 2024;31:329-334.
    >> Share

  18. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening.
    Breast Cancer. 2024;31:228-233.
    >> Share


    Breast Cancer (Auckl)

  19. PREMJI SK, O'Sullivan CC
    Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options.
    Breast Cancer (Auckl). 2024;18:11782234241234418.
    >> Share


    Breast Cancer Res

  20. SONG T, Zhang H, Zhao Q, Hu Z, et al
    Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Breast Cancer Res. 2024;26:33.
    >> Share

  21. EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
    PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
    Breast Cancer Res. 2024;26:34.
    >> Share

  22. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
    Breast Cancer Res. 2024;26:32.
    >> Share

  23. JUNG M, Song SG, Cho SI, Shin S, et al
    Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Breast Cancer Res. 2024;26:31.
    >> Share


    Breast Cancer Res Treat

  24. VOETS MM, Hassink NS, Veltman J, Slump CH, et al
    Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.
    Breast Cancer Res Treat. 2024 Feb 26. doi: 10.1007/s10549-024-07246.
    >> Share

  25. HOSSEINI Y, Hadi Sichani P, Moslemi E, Nouri M, et al
    Pro-vegetarian dietary pattern and risk of breast cancer: a case-control study.
    Breast Cancer Res Treat. 2024 Feb 28. doi: 10.1007/s10549-024-07243.
    >> Share

  26. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
    Development of a core outcome set for breast cancer-related lymphedema: a Delphi study.
    Breast Cancer Res Treat. 2024 Feb 29. doi: 10.1007/s10549-024-07262.
    >> Share

  27. WU Y, Li Z, Lee AV, Oesterreich S, et al
    Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
    Breast Cancer Res Treat. 2024 Mar 1. doi: 10.1007/s10549-024-07255.
    >> Share


    Breast J

  28. SELAMIOGLU E, Agdogan O
    Mammoplasty Using Modified Superomedial Pedicle Technique in Severely Macromastia and Ptotic Breasts.
    Breast J. 2024;2024:7635485.
    >> Share


    Cancer

  29. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    >> Share

  30. HOU X, Li X, Han Y, Xu H, et al
    Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
    >> Share

  31. NIERENGARTEN MB
    FDA approves capivasertib with fulvestrant for breast cancer.
    Cancer. 2024;130:835-836.
    >> Share


    Cancer Chemother Pharmacol

  32. MITTRA A, Coyne GHOS, Zlott J, Kummar S, et al
    Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Cancer Chemother Pharmacol. 2024;93:177-189.
    >> Share


    Cancer Epidemiol Biomarkers Prev

  33. FARBER R, Houssami N, McGeechan K, Barratt A, et al
    Breast cancer stage and size detected with film versus digital mammography in New South Wales, Australia: a population-based study using routinely collected data.
    Cancer Epidemiol Biomarkers Prev. 2024.
    >> Share


    Cancer Lett

  34. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    >> Share

  35. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    >> Share

  36. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    >> Share


    Clin Breast Cancer

  37. REYES A, Sun L, Ha R, Desperito E, et al
    A Comprehensive Assessment of Radial Scars on Core Needle Biopsy in Patients with or without Breast Cancer: Upgrade Rate and Implications on Management.
    Clin Breast Cancer. 2024 Feb 1:S1526-8209(24)00035.
    >> Share

  38. SONOLA O
    Re: "Diagnostic Delays in Breast Cancer Among Young Women: An Emphasis on Healthcare Providers" by Costa et al.
    Clin Breast Cancer. 2024 Feb 6:S1526-8209(24)00038.
    >> Share

  39. YOU YH, Kim MK, Lee JY
    Prognosis and Adjusting Factors in Elderly Patients With Triple-Negative Breast Cancer: Comparing With Young and Middle Age Groups.
    Clin Breast Cancer. 2024 Jan 30:S1526-8209(24)00027.
    >> Share

  40. KAVISHAHI NN, Rezaee A, Jalalian S
    The Impact of miRNAs on the Efficacy of Tamoxifen in Breast Cancer Treatment: A Systematic Review.
    Clin Breast Cancer. 2024 Jan 26:S1526-8209(24)00026.
    >> Share

  41. METIN NO, Balci S, Metin Y, Tasci F, et al
    Correlation Between Quantitative Parameters Obtained by Dual Energy Spectral CT and Prognostic Histopathological Factors and Biomarkers in Breast Cancer.
    Clin Breast Cancer. 2024 Feb 1:S1526-8209(24)00037.
    >> Share


    Eur J Surg Oncol

  42. VAN DAM MA, Bijlstra OD, Faber RA, Warmerdam MI, et al
    Consensus conference statement on fluorescence-guided surgery (FGS) ESSO course on fluorescence-guided surgery.
    Eur J Surg Oncol. 2024;50:107317.
    >> Share

  43. SKJERVEN HK, Myklebust EM, Korvald C, Stubberud K, et al
    Long-term follow-up of complex oncoplastic breast-conserving surgery, standard breast conservation and skin-sparing mastectomy in DCIS - a register-based study.
    Eur J Surg Oncol. 2024;50:107938.
    >> Share


    Eur Radiol

  44. KOCH HW, Larsen M, Bartsch H, Martiniussen MA, et al
    How do AI markings on screening mammograms correspond to cancer location? An informed review of 270 breast cancer cases in BreastScreen Norway.
    Eur Radiol. 2024 Feb 23. doi: 10.1007/s00330-024-10662.
    >> Share


    Exp Cell Res

  45. SHI X, Sun Y, Zhang Y, Wang W, et al
    Corrigendum to "MEX3A promotes development and progression of breast cancer through regulation of PIK3CA" [Exp. Cell Res. 2021 Jul 1;404(1):112580. Epub 2021 Apr 1.].
    Exp Cell Res. 2024;436:113964.
    >> Share


    Int J Oncol

  46. MBUGUA RW, Takano A, Tsevegjav B, Yokose T, et al
    Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer.
    Int J Oncol. 2024;64:43.
    >> Share


    Int J Radiat Oncol Biol Phys

  47. GRENDAROVA P, Roumeliotis M, Quirk S, Phan T, et al
    Accelerated Partial Breast Irradiation Using 5 Daily Fractions: A Prospective, Phase 2, Multicenter Trial of Cosmetic Outcomes and Toxicity-ACCEL Final Results.
    Int J Radiat Oncol Biol Phys. 2024;118:1041-1048.
    >> Share

  48. LAUGHLIN BS, Corbin KS, Toesca DAS, Thorpe CS, et al
    Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery.
    Int J Radiat Oncol Biol Phys. 2024;118:1049-1059.
    >> Share

  49. SILVERWOOD S, Lichter K, Conway A, Drew T, et al
    Distance Traveled by Patients Globally to Access Radiation Therapy: A Systematic Review.
    Int J Radiat Oncol Biol Phys. 2024;118:891-899.
    >> Share


    J Clin Oncol

  50. WORIAX HE, Thomas SM, Plichta JK, Rosenberger LH, et al
    Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
    J Clin Oncol. 2024 Feb 23:JCO2301199. doi: 10.1200/JCO.23.01199.
    >> Share


  51. Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
    J Clin Oncol. 2024 Feb 23:JCO2400317. doi: 10.1200/JCO.24.00317.
    >> Share

  52. MAXWELL KN, Domchek SM
    Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.
    J Clin Oncol. 2024 Feb 29:JCO2400029. doi: 10.1200/JCO.24.00029.
    >> Share

  53. BARDIA A, Rugo HS, Tolaney SM, Loirat D, et al
    Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    J Clin Oncol. 2024 Feb 29:JCO2301409. doi: 10.1200/JCO.23.01409.
    >> Share

  54. MARS N, Kerminen S, Tamlander M, Pirinen M, et al
    Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
    J Clin Oncol. 2024 Feb 29:JCO2300295. doi: 10.1200/JCO.23.00295.
    >> Share


    J Natl Cancer Inst

  55. LI JL, McClellan JC, Zhang H, Gao G, et al
    Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
    J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
    >> Share


    Lancet Oncol

  56. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
    Non-surgical ablation for breast cancer: an emerging therapeutic option.
    Lancet Oncol. 2024;25:e114-e125.
    >> Share


    Mod Pathol

  57. DERAKHSHAN F, Da Cruz Paula A, Selenica P, da Silva EM, et al
    Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Mod Pathol. 2024;37:100375.
    >> Share

  58. SHAFIQUE A, Gonzalez R, Pantanowitz L, Tan PH, et al
    A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.
    Mod Pathol. 2024;37:100381.
    >> Share


    NPJ Breast Cancer

  59. ALKHAFAJI S, Wolf DM, Magbanua MJM, J van 't Veer L, et al
    Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    NPJ Breast Cancer. 2024;10:17.
    >> Share

  60. LIU H, Xie X, Wang B
    Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images.
    NPJ Breast Cancer. 2024;10:18.
    >> Share


    Oncogene

  61. BARRA J, Crosbourne I, Roberge CL, Bossardi-Ramos R, et al
    DMT1-dependent endosome-mitochondria interactions regulate mitochondrial iron translocation and metastatic outgrowth.
    Oncogene. 2024;43:650-667.
    >> Share

  62. ZHENG XQ, Guo JP, Yang H, Kanai M, et al
    Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02983.
    >> Share

  63. YANG L, Wang M, Wang Y, Zhu Y, et al
    LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02972.
    >> Share

  64. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02990.
    >> Share


    Oncology

  65. ZAVESKY L, Jandakova E, Weinberger V, Minar L, et al
    Human endogenous retroviruses (HERVs) in breast cancer: altered expression pattern implicates divergent roles in carcinogenesis.
    Oncology. 2024 Feb 26. doi: 10.1159/000538021.
    >> Share


    PLoS One

  66. KUO ET, Kuo C, Lin CL
    Inhaled anesthesia associated with reduced mortality in patients with stage III breast cancer: A population-based study.
    PLoS One. 2024;19:e0289519.
    >> Share

  67. NYAMHANGA T, Eustace RW, Makoye JP, Mutalemwa K, et al
    Multi-level barriers to early detection of breast cancer among rural midlife women in Tanzania: A qualitative case study.
    PLoS One. 2024;19:e0297798.
    >> Share

  68. MILLER JL, Reddy A, Harman RM, Van de Walle GR, et al
    A xenotransplantation mouse model to study physiology of the mammary gland from large mammals.
    PLoS One. 2024;19:e0298390.
    >> Share

  69. XIA Q, Shen J, Wang Q, Chen R, et al
    Cuproptosis-associated ncRNAs predict breast cancer subtypes.
    PLoS One. 2024;19:e0299138.
    >> Share

  70. BAKER R, Dell'Acqua G, Richards A, Thornton MJ, et al
    Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in MCF7, T47D and BT483 breast cancer cell lines.
    PLoS One. 2024;19:e0297080.
    >> Share

  71. WIRANATA JA, Hutajulu SH, Astari YK, Leo B, et al
    Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer.
    PLoS One. 2024;19:e0298928.
    >> Share

  72. TAOMA K, Ruengjitchatchawalya M, Liangruksa M, Laomettachit T, et al
    Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy.
    PLoS One. 2024;19:e0298788.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016